author-photo

Raymond P. Perez

University of Kansas
Roswell Park Cancer Institute
Fox Chase Cancer Center

106

Papers

2530

Citations

Citation Trend

Filter By

Papers (106) Sort By

Journal Conference Others

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

2020 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (24)
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

2020 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

2020 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
The effect of Sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors.

2020 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib plus Dexamethasone in Relapsed Multiple Myeloma.

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (32)
Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies

2019 Pharmacology Research & Perspectives
Show All
- Source
- Cite
- Save
Citations (1)
Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study

2018
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (94)
Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (24)
Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)